{"entity":{"type":"insider","cik":"0001677345","url":"/insider/0001677345","json_url":"/insider/0001677345.json","name":"Flagship Ventures Opportunities Fund I, L.P.","name_source":"as-filed","also_issuer":false,"cross_url":null},"coverage_statement":{"n_transactions":41,"n_filings":13,"first":"2018-05-15","last":"2022-10-17","span_basis":"filed_date"},"name_variants":[{"name":"Flagship Ventures Opportunities Fund I, L.P.","source":"filing","n_filings":13,"first_seen":"2018-05-15","last_seen":"2022-10-17"}],"transactions":[{"id":6645696,"accession":"0000899243-22-033703","txn_seq":5,"anchor":"line-5","filing_url":"/filing/0000899243-22-033703","line_url":"/filing/0000899243-22-033703","is_derivative":false,"issuer_cik":"0001222012","issuer_name":"Axcella Health Inc.","issuer_ticker":"AXLA","issuer_name_source":null,"issuer_url":"/issuer/0001222012","owner_cik":null,"owner_name":"Flagship Ventures Opportunities Fund I General Partner LLC; Flagship Ventures Opportunities Fund I, L.P.; Flagship Ventures Fund IV, L.P.; Flagship Ventures Fund IV General Partner LLC; AFEYAN NOUBAR","owner_display_name":"Flagship Ventures Opportunities Fund I General Partner LLC","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":5,"other_reporting_owners":4,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":10383760.0,"shares_display":"10,383,760","price_per_share":1.64,"price_display":"1.64","price_state":"stated","total_value":17029366.4,"total_display":"17,029,366.40","total_whole":"17,029,366","shares_owned_after":3048780.0,"shares_owned_after_display":"3,048,780","ownership_form":"I","is_10b5_1":null,"transaction_date":"2022-10-13","filed_date":"2022-10-17","scope":"insider","n_lines":5},{"id":6386114,"accession":"0000899243-22-020533","txn_seq":5,"anchor":"line-5","filing_url":"/filing/0000899243-22-020533","line_url":"/filing/0000899243-22-020533","is_derivative":false,"issuer_cik":"0001222012","issuer_name":"Evelo Biosciences, Inc.","issuer_ticker":"EVLO","issuer_name_source":null,"issuer_url":"/issuer/0001222012","owner_cik":null,"owner_name":"Flagship Ventures Fund IV General Partner LLC; Nutritional Health LTP Fund, L.P.; Flagship Ventures Opportunities Fund I, L.P.; Flagship Ventures Fund IV-Rx, L.P.; Nutritional Health LTP Fund General Partner LLC; AFEYAN NOUBAR; Flagship Pioneering Inc.; Flagship Ventures Opportunities Fund I General Partner LLC; Flagship Ventures Fund IV, L.P.","owner_display_name":"Flagship Ventures Fund IV General Partner LLC","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":9,"other_reporting_owners":8,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":27397259.0,"shares_display":"27,397,259","price_per_share":1.46,"price_display":"1.46","price_state":"stated","total_value":39999998.14,"total_display":"39,999,998.14","total_whole":"39,999,998","shares_owned_after":13698630.0,"shares_owned_after_display":"13,698,630","ownership_form":"I","is_10b5_1":null,"transaction_date":"2022-05-27","filed_date":"2022-06-01","scope":"insider","n_lines":5},{"id":6691040,"accession":"0000899243-22-011535","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0000899243-22-011535","line_url":"/filing/0000899243-22-011535","is_derivative":false,"issuer_cik":"0001222012","issuer_name":"Axcella Health Inc.","issuer_ticker":"AXLA","issuer_name_source":null,"issuer_url":"/issuer/0001222012","owner_cik":null,"owner_name":"Flagship Ventures Fund IV General Partner LLC; Flagship Ventures Opportunities Fund I General Partner LLC; Flagship Ventures Fund IV, L.P.; AFEYAN NOUBAR; Flagship Ventures Opportunities Fund I, L.P.; Flagship Ventures Fund IV-Rx, L.P.","owner_display_name":"Flagship Ventures Fund IV General Partner LLC","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":6,"other_reporting_owners":5,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":6319371.0,"shares_display":"6,319,371","price_per_share":1.91,"price_display":"1.91","price_state":"stated","total_value":12069998.61,"total_display":"12,069,998.61","total_whole":"12,069,999","shares_owned_after":8600403.0,"shares_owned_after_display":"8,600,403","ownership_form":"I","is_10b5_1":null,"transaction_date":"2022-03-16","filed_date":"2022-03-18","scope":"insider","n_lines":3},{"id":5391706,"accession":"0000899243-21-013179","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0000899243-21-013179","line_url":"/filing/0000899243-21-013179","is_derivative":false,"issuer_cik":"0001222012","issuer_name":"Rubius Therapeutics, Inc.","issuer_ticker":"RUBY","issuer_name_source":null,"issuer_url":"/issuer/0001222012","owner_cik":null,"owner_name":"AFEYAN NOUBAR; Flagship Ventures Fund V, L.P.; Flagship Ventures Fund V General Partner LLC; Flagship Ventures Opportunities Fund I General Partner LLC; Flagship Ventures Fund IV General Partner LLC; Flagship Ventures Fund IV, L.P.; Flagship Ventures Opportunities Fund I, L.P.","owner_display_name":"AFEYAN NOUBAR","owner_url":null,"role":"Director, Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":7,"other_reporting_owners":6,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":210000.0,"shares_display":"210,000","price_per_share":29.0,"price_display":"29.00","price_state":"stated","total_value":6090000.0,"total_display":"6,090,000.00","total_whole":"6,090,000","shares_owned_after":15393593.0,"shares_owned_after_display":"15,393,593","ownership_form":"I","is_10b5_1":null,"transaction_date":"2021-03-19","filed_date":"2021-03-23","scope":"insider","n_lines":3},{"id":5454845,"accession":"0000899243-21-005713","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0000899243-21-005713","line_url":"/filing/0000899243-21-005713","is_derivative":false,"issuer_cik":"0001222012","issuer_name":"Kaleido Biosciences, Inc.","issuer_ticker":"KLDO","issuer_name_source":null,"issuer_url":"/issuer/0001222012","owner_cik":null,"owner_name":"AFEYAN NOUBAR; Nutritional Health LTP Fund, L.P.; Nutritional Health LTP Fund General Partner LLC; Flagship Ventures Fund IV General Partner LLC; Flagship Ventures Opportunities Fund I, L.P.; Flagship Ventures Fund IV, L.P.; Flagship Ventures Opportunities Fund I General Partner LLC","owner_display_name":"AFEYAN NOUBAR","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":7,"other_reporting_owners":6,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":215000.0,"shares_display":"215,000","price_per_share":11.5,"price_display":"11.50","price_state":"stated","total_value":2472500.0,"total_display":"2,472,500.00","total_whole":"2,472,500","shares_owned_after":2982639.0,"shares_owned_after_display":"2,982,639","ownership_form":"I","is_10b5_1":null,"transaction_date":"2021-02-08","filed_date":"2021-02-10","scope":"insider","n_lines":3},{"id":5275511,"accession":"0000899243-21-004962","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0000899243-21-004962","line_url":"/filing/0000899243-21-004962","is_derivative":false,"issuer_cik":"0001222012","issuer_name":"Evelo Biosciences, Inc.","issuer_ticker":"EVLO","issuer_name_source":null,"issuer_url":"/issuer/0001222012","owner_cik":null,"owner_name":"Flagship Ventures Fund IV General Partner LLC; Flagship Ventures Opportunities Fund I General Partner LLC; Flagship Ventures Fund IV, L.P.; AFEYAN NOUBAR; Flagship Ventures Opportunities Fund I, L.P.; Nutritional Health LTP Fund, L.P.; Flagship Ventures Fund IV-Rx, L.P.; Nutritional Health LTP Fund General Partner LLC","owner_display_name":"Flagship Ventures Fund IV General Partner LLC","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":8,"other_reporting_owners":7,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":130000.0,"shares_display":"130,000","price_per_share":15.0,"price_display":"15.00","price_state":"stated","total_value":1950000.0,"total_display":"1,950,000.00","total_whole":"1,950,000","shares_owned_after":4125461.0,"shares_owned_after_display":"4,125,461","ownership_form":"I","is_10b5_1":null,"transaction_date":"2021-02-02","filed_date":"2021-02-04","scope":"insider","n_lines":4},{"id":3239887,"accession":"0000899243-20-029693","txn_seq":8,"anchor":"line-8","filing_url":"/filing/0000899243-20-029693","line_url":"/filing/0000899243-20-029693","is_derivative":false,"issuer_cik":"0001222012","issuer_name":"Foghorn Therapeutics Inc.","issuer_ticker":"FHTX","issuer_name_source":null,"issuer_url":"/issuer/0001222012","owner_cik":null,"owner_name":"Flagship Pioneering Inc.; AFEYAN NOUBAR; Flagship Ventures Fund V General Partner LLC; Flagship Ventures Fund V, L.P.; Flagship Ventures Opportunities Fund I, L.P.; Flagship Pioneering Special Opportunities Fund II, L.P.; Flagship Pioneering Special Opportunities Fund II General Partner LLC; Flagship Ventures Opportunities Fund I General Partner LLC","owner_display_name":"Flagship Pioneering Inc.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":8,"other_reporting_owners":7,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":150000.0,"shares_display":"150,000","price_per_share":16.0,"price_display":"16.00","price_state":"stated","total_value":2400000.0,"total_display":"2,400,000.00","total_whole":"2,400,000","shares_owned_after":9330878.0,"shares_owned_after_display":"9,330,878","ownership_form":"I","is_10b5_1":null,"transaction_date":"2020-10-27","filed_date":"2020-10-29","scope":"insider","n_lines":3},{"id":2857666,"accession":"0000899243-20-018150","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0000899243-20-018150","line_url":"/filing/0000899243-20-018150","is_derivative":false,"issuer_cik":"0001222012","issuer_name":"Evelo Biosciences, Inc.","issuer_ticker":"EVLO","issuer_name_source":null,"issuer_url":"/issuer/0001222012","owner_cik":null,"owner_name":"Flagship Ventures Fund IV-Rx, L.P.; AFEYAN NOUBAR; Flagship Ventures Opportunities Fund I General Partner LLC; Flagship Ventures Opportunities Fund I, L.P.; Flagship Ventures Fund IV General Partner LLC; Flagship Ventures Fund IV, L.P.","owner_display_name":"Flagship Ventures Fund IV-Rx, L.P.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":6,"other_reporting_owners":5,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":4666666.0,"shares_display":"4,666,666","price_per_share":3.75,"price_display":"3.75","price_state":"stated","total_value":17499997.5,"total_display":"17,499,997.50","total_whole":"17,499,998","shares_owned_after":4079032.0,"shares_owned_after_display":"4,079,032","ownership_form":"I","is_10b5_1":null,"transaction_date":"2020-06-29","filed_date":"2020-07-01","scope":"insider","n_lines":4},{"id":2986784,"accession":"0000899243-20-015630","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0000899243-20-015630","line_url":"/filing/0000899243-20-015630","is_derivative":false,"issuer_cik":"0001222012","issuer_name":"Kaleido Biosciences, Inc.","issuer_ticker":"KLDO","issuer_name_source":null,"issuer_url":"/issuer/0001222012","owner_cik":null,"owner_name":"Flagship Ventures Opportunities Fund I General Partner LLC; Flagship Ventures Fund IV General Partner LLC; Flagship Ventures Opportunities Fund I, L.P.; AFEYAN NOUBAR; Flagship Ventures Fund IV, L.P.","owner_display_name":"Flagship Ventures Opportunities Fund I General Partner LLC","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":5,"other_reporting_owners":4,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":2000000.0,"shares_display":"2,000,000","price_per_share":7.5,"price_display":"7.50","price_state":"stated","total_value":15000000.0,"total_display":"15,000,000.00","total_whole":"15,000,000","shares_owned_after":2910972.0,"shares_owned_after_display":"2,910,972","ownership_form":"I","is_10b5_1":null,"transaction_date":"2020-06-04","filed_date":"2020-06-08","scope":"insider","n_lines":3},{"id":2456042,"accession":"0000899243-20-013708","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0000899243-20-013708","line_url":"/filing/0000899243-20-013708","is_derivative":false,"issuer_cik":"0001222012","issuer_name":"Axcella Health Inc.","issuer_ticker":"AXLA","issuer_name_source":null,"issuer_url":"/issuer/0001222012","owner_cik":null,"owner_name":"Flagship Ventures Fund IV, L.P.; Flagship Ventures Opportunities Fund I General Partner LLC; Flagship Ventures Fund IV General Partner LLC; AFEYAN NOUBAR; Flagship Ventures Opportunities Fund I, L.P.; Flagship Ventures Fund IV-Rx, L.P.","owner_display_name":"Flagship Ventures Fund IV, L.P.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":6,"other_reporting_owners":5,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":3800000.0,"shares_display":"3,800,000","price_per_share":4.75,"price_display":"4.75","price_state":"stated","total_value":18050000.0,"total_display":"18,050,000.00","total_whole":"18,050,000","shares_owned_after":2886023.0,"shares_owned_after_display":"2,886,023","ownership_form":"I","is_10b5_1":null,"transaction_date":"2020-05-18","filed_date":"2020-05-20","scope":"insider","n_lines":3},{"id":8667371,"accession":"0001104659-19-029735","txn_seq":12,"anchor":"line-12","filing_url":"/filing/0001104659-19-029735","line_url":"/filing/0001104659-19-029735#line-12","is_derivative":false,"issuer_cik":"0001222012","issuer_name":"Axcella Health Inc.","issuer_ticker":"AXLA","issuer_name_source":null,"issuer_url":"/issuer/0001222012","owner_cik":null,"owner_name":"Flagship Ventures Fund IV-Rx, L.P.; Flagship Ventures Opportunities Fund I, L.P.; AFEYAN NOUBAR; Flagship Ventures Fund 2007, L.P.; Flagship Ventures Fund IV General Partner LLC; Flagship Ventures 2007 General Partner LLC; Flagship Ventures Fund IV, L.P.; Flagship Ventures Opportunities Fund I General Partner LLC; Flagship VentureLabs IV, LLC; KANIA EDWIN M JR","owner_display_name":"Flagship Ventures Fund IV-Rx, L.P.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":10,"other_reporting_owners":9,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":500000.0,"shares_display":"500,000","price_per_share":20.0,"price_display":"20.00","price_state":"stated","total_value":10000000.0,"total_display":"10,000,000.00","total_whole":"10,000,000","shares_owned_after":986023.0,"shares_owned_after_display":"986,023","ownership_form":"I","is_10b5_1":null,"transaction_date":"2019-05-13","filed_date":"2019-05-15","scope":"insider"},{"id":8436925,"accession":"0000899243-19-006455","txn_seq":12,"anchor":"line-12","filing_url":"/filing/0000899243-19-006455","line_url":"/filing/0000899243-19-006455","is_derivative":false,"issuer_cik":"0001222012","issuer_name":"Kaleido Biosciences, Inc.","issuer_ticker":"KLDO","issuer_name_source":null,"issuer_url":"/issuer/0001222012","owner_cik":null,"owner_name":"Flagship Ventures Opportunities Fund I General Partner LLC; Flagship Pioneering Inc.; Flagship VentureLabs V LLC; Flagship Ventures Fund V General Partner LLC; Nutritional Health Disruptive Innovation Fund, L.P.; Flagship Ventures Fund V, L.P.; AFEYAN NOUBAR; Flagship Ventures Opportunities Fund I, L.P.; Flagship VentureLabs V Manager LLC; Nutritional Health Side Fund, L.P.","owner_display_name":"Flagship Ventures Opportunities Fund I General Partner LLC","owner_url":null,"role":"Director, Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":10,"other_reporting_owners":9,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":933333.0,"shares_display":"933,333","price_per_share":15.0,"price_display":"15.00","price_state":"stated","total_value":13999995.0,"total_display":"13,999,995.00","total_whole":"13,999,995","shares_owned_after":6560523.0,"shares_owned_after_display":"6,560,523","ownership_form":"I","is_10b5_1":null,"transaction_date":"2019-03-04","filed_date":"2019-03-06","scope":"insider","n_lines":3},{"id":6007977,"accession":"0000899243-18-013013","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0000899243-18-013013","line_url":"/filing/0000899243-18-013013#line-2","is_derivative":false,"issuer_cik":"0001222012","issuer_name":"Evelo Biosciences, Inc.","issuer_ticker":"EVLO","issuer_name_source":null,"issuer_url":"/issuer/0001222012","owner_cik":null,"owner_name":"Flagship V VentureLabs Rx Fund, L.P.; KANIA EDWIN M JR; Flagship Ventures Opportunities Fund I General Partner LLC; Flagship VentureLabs V LLC; Flagship Ventures Fund V General Partner LLC; Nutritional Health Disruptive Innovation Fund, L.P.; Flagship Ventures Fund V, L.P.; AFEYAN NOUBAR; Flagship Ventures Opportunities Fund I, L.P.; Nutritional Health Side Fund, L.P.","owner_display_name":"Flagship V VentureLabs Rx Fund, L.P.","owner_url":null,"role":"Director, Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":10,"other_reporting_owners":9,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":281250.0,"shares_display":"281,250","price_per_share":16.0,"price_display":"16.00","price_state":"stated","total_value":4500000.0,"total_display":"4,500,000.00","total_whole":"4,500,000","shares_owned_after":18233403.0,"shares_owned_after_display":"18,233,403","ownership_form":"I","is_10b5_1":null,"transaction_date":"2018-05-11","filed_date":"2018-05-15","scope":"insider"}],"collapsed":true,"next_cursor":null,"ledger_fault":false,"count":{"value":0,"kind":"exact"},"open_market_only":false,"composition":{"kind":"exact","rows":[{"code":"P","label":"Open-market purchase","n":0,"open_market":true},{"code":"S","label":"Open-market sale","n":0,"open_market":true},{"code":"M","label":"Option exercise","n":0,"open_market":false},{"code":"A","label":"Grant or award","n":0,"open_market":false},{"code":"F","label":"Tax withholding","n":0,"open_market":false},{"code":"D","label":"Disposition to the issuer","n":0,"open_market":false},{"code":"X","label":"In-the-money option exercise","n":0,"open_market":false}],"total":0},"affiliations":[{"type":"issuer","type_label":"ISSUER","cik":"0001633070","name":"Axcella Health Inc.","url":"/issuer/0001633070","role":"Ten percent owner","n_filings":4,"first_seen":"2019-05-15","last_seen":"2022-10-17"},{"type":"issuer","type_label":"ISSUER","cik":"0001694665","name":"Evelo Biosciences, Inc.","url":"/issuer/0001694665","role":"Ten percent owner","n_filings":4,"first_seen":"2018-05-15","last_seen":"2022-06-01"},{"type":"issuer","type_label":"ISSUER","cik":"0001709401","name":"Rubius Therapeutics, Inc.","url":"/issuer/0001709401","role":"Ten percent owner","n_filings":1,"first_seen":"2021-03-23","last_seen":"2021-03-23"},{"type":"issuer","type_label":"ISSUER","cik":"0001751299","name":"Kaleido Biosciences, Inc.","url":"/issuer/0001751299","role":"Ten percent owner","n_filings":3,"first_seen":"2019-03-06","last_seen":"2021-02-10"},{"type":"issuer","type_label":"ISSUER","cik":"0001822462","name":"Foghorn Therapeutics Inc.","url":"/issuer/0001822462","role":"Ten percent owner","n_filings":1,"first_seen":"2020-10-29","last_seen":"2020-10-29"}],"order_statement":"Newest transaction date first, id breaking the tie.","canonical_url":"https://ebomi.com/insider/0001677345","retrieved_at":"2026-08-22T20:15:28+00:00","coverage":{"filings":1506293,"transactions":4290787,"issuers":28597,"insiders":152303,"first_filed_date":"2003-06-30","last_filed_date":"2026-08-21","last_ingest":"2026-08-22T05:23:40.159918+00:00","counts_are":{"filings":"estimate","transactions":"estimate","issuers":"estimate","insiders":"estimate"},"source":"SEC EDGAR Form 4 filings, parsed by ebomi","fault":false},"license":{"underlying_records":"US SEC filings are public records of the United States government and are not subject to copyright. The transactional facts in them are not ours to license.","this_presentation":"The parsing, normalisation, curation, and presentation are ebomi's own work.","grant":"undecided","grant_note":"The open licence for ebomi's own layer is an open owner decision (SPEC-20260731T1159Z open question 3: CC BY 4.0 or CC0 with a citation request). Until it is taken, no grant is asserted here.","citation_request":"Balogh, A. Insider trading. Scientific Data 10, 237 (2023)","url":"https://ebomi.com/license"},"fair_use":{"policy":"These JSON endpoints are open and unauthenticated. Please read them at a human pace, identify your client in the User-Agent header, and use the published dataset for bulk work rather than crawling page by page.","bulk_alternative":"doi:10.1038/s41597-023-02147-6"}}